8-K: FOXO Technologies Inc. Faces NYSE Non-Compliance Notice Due to Stockholders' Deficit and Losses

FOXO Technologies Inc. has received a notice from the NYSE American stating the company is not in compliance with listing standards due to a stockholders' deficit of $14.9 million and recent losses.

Summary

• FOXO Technologies Inc. has received a non-compliance notice from the NYSE American due to a stockholders' deficit of $14.9 million as of March 31, 2024.
• The company has also reported losses from continuing operations and/or net losses in its three most recent fiscal years ended December 31, 2023.
• This non-compliance is related to Section 1003(a)(ii) of the NYSE Company Guide.
• FOXO is now subject to the procedures and requirements set forth in Section 1009 of the Company Guide.
• The company is also still under conditions from previous NYSE letters regarding stockholders' equity and past due listing fees.
• If FOXO does not meet compliance deadlines or make sufficient progress, the NYSE may initiate delisting proceedings.
• FOXO intends to submit a compliance plan and regain compliance with NYSE American listing standards.
• The company has contacted the NYSE to confirm receipt of the notice and discuss recent developments.

Sentiment

Score: 3

Explanation: The document highlights significant financial issues and the risk of delisting, leading to a negative sentiment. While the company expresses intent to regain compliance, the current situation is concerning.

Positives

• FOXO is in contact with the NYSE and plans to present a compliance plan.
• The company believes recent planned acquisitions will generate meaningful cash flow for the combined companies.
• FOXO intends to regain compliance with the NYSE American continued listing standards.

Negatives

• FOXO has a stockholders' deficit of $14.9 million as of March 31, 2024.
• The company has reported losses in its three most recent fiscal years.
• FOXO is not in compliance with Section 1003(a)(ii) of the NYSE Company Guide.
• The company is subject to potential delisting if compliance is not achieved.
• The company is also under conditions from previous NYSE letters regarding stockholders' equity and past due listing fees.

Risks

• There is no assurance that FOXO will regain compliance with NYSE American listing standards.
• The company faces the risk of delisting if it does not meet compliance deadlines or make sufficient progress.
• The company's ability to implement its business plans and obtain financing is uncertain.
• FOXO has a history of losses and may not achieve or maintain profitability in the future.
• The company faces risks related to competition, regulation, and intellectual property.

Future Outlook

FOXO intends to regain compliance with NYSE American listing standards and believes planned acquisitions will generate meaningful cash flow, but there is no assurance of success.

Management Comments

• Mark White, Interim CEO of FOXO, stated that the delinquency was due to previously disclosed short-term capital allocation strategies.
• He also mentioned that they have been in contact with NYSE and look forward to presenting their compliance plan.
• Management believes recent acquisitions will generate meaningful cash flow for the combined companies.

Industry Context

The biotechnology industry is highly competitive and regulated, and FOXO's non-compliance highlights the financial challenges faced by some companies in this sector. The company's focus on epigenetic technology and AI in life insurance is a niche area, and its success depends on its ability to commercialize its technology and achieve profitability.

Comparison to Industry Standards

• Many biotechnology companies, especially those in early stages, face challenges in maintaining profitability and meeting listing requirements.
• Companies like 23andMe (ME) and Ginkgo Bioworks (DNA) have also faced scrutiny regarding their financial performance and ability to achieve profitability.
• The specific listing requirements of the NYSE American exchange are designed to ensure a minimum level of financial stability and investor confidence.
• FOXO's situation is not unique, but the severity of the stockholders' deficit and the history of losses place it in a more precarious position compared to some peers.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment.
• Employees may experience uncertainty due to the company's financial challenges.
• Customers and partners may be concerned about the company's long-term viability.
• Creditors may be at risk if the company's financial situation does not improve.

Next Steps

• FOXO will submit a compliance plan to the NYSE.
• The company will work to regain compliance with NYSE American listing standards.
• FOXO will continue to discuss recent developments with NYSE staff.

Key Dates

Keywords

NYSE American, non-compliance, delisting, stockholders' deficit, listing standards, compliance plan, losses, biotechnology, epigenetic technology, financial health